0 TSX Venture News - May 23, 2024Tornado Global Hydrovacs Reports First Quarter 2024 ResultsCALGARY, May 23, 2024 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado” or the “Company”) (TSX-V: TGH; OTCQX: TGHLF) today […]Read More
0 NASDAQ Companies - May 23, 2024LexinFintech Holdings Ltd. Reports First Quarter 2024 Unaudited Financial ResultsSHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered […]Read More
0 TSX Venture News - May 23, 2024Western Pacific Trust Company Announces Q1-2024 ResultsVANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) — WESTERN PACIFIC TRUST COMPANY (TSXV: WP) announces its financial results for […]Read More
0 NASDAQ Companies - May 23, 2024Huize Holding Limited Reports First Quarter 2024 Unaudited Financial ResultsSHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) — Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading […]Read More
0 NASDAQ Companies - May 23, 2024Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual MeetingSALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and […]Read More
0 NYSE Companies - May 23, 2024Le conseil d’administration de Gildan démissionne• Vince Tyra a quitté ses fonctions de président et chef de la direction• Fin du processus de vente MONTRÉAL, […]Read More
0 NYSE Companies - May 23, 2024Gildan Board of Directors ResignsVince Tyra has Stepped Down as President and CEO Sale Process has Ceased MONTREAL, May 23, 2024 (GLOBE NEWSWIRE) — […]Read More
0 TSX Venture News - May 23, 2024Acceleware Ltd. Reports First Quarter 2024 Financial and Operating ResultsCALGARY, Alberta, May 23, 2024 (GLOBE NEWSWIRE) — Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), a leading innovator of […]Read More
0 NASDAQ Companies - May 23, 2024Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors […]Read More
0 NASDAQ Companies - May 23, 2024CORRECTION – The Herzfeld Caribbean Basin Fund, Inc. Announces Distribution in Stock and CashMIAMI BEACH, Fla., May 23, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by […]Read More